000246855 000__ 01748cam\a2200373\a\45e0
000246855 001__ 246855
000246855 005__ 20220217104533.0
000246855 008__ 010315s2000\\\\dcua\\\\\b\\\f001\0\eng\c
000246855 020__ $$a0160647290
000246855 035__ $$a(OCoLC)ocm46457094
000246855 035__ $$a246855
000246855 040__ $$aGPO$$cGPO
000246855 042__ $$apcc
000246855 043__ $$an-us---
000246855 049__ $$aISEA
000246855 074__ $$a1015-A
000246855 074__ $$a1015-B (MF)
000246855 0860_ $$aY 4.ED 8/1:106-130
000246855 088__ $$aSerial no. 106-130 (United States. Congress. House. Committee on Education and the Workforce)
000246855 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Education and the Workforce.$$bSubcommittee on Oversight and Investigations.
000246855 24510 $$aBehavioral drugs in schools :$$bquestions and concerns : hearing before the Subcommittee on Oversight and Investigations of the Committee on Education and the Workforce, House of Representatives, One Hundred Sixth Congress, second session, hearing held in Washington, DC, September 29, 2000.
000246855 260__ $$aWashington :$$bU.S. G.P.O. :$$b[U.S. G.P.O., Supt. of Docs., Congressional Sales Office, distributor],$$c2000.
000246855 300__ $$av, 359 p. :$$bill. ;$$c24 cm.
000246855 500__ $$aDistributed to some depository libraries in microfiche.
000246855 500__ $$aShipping list no.: 2001-0125-P.
000246855 500__ $$a"Serial no. 106-130."
000246855 504__ $$aIncludes bibliographical references and index.
000246855 650_0 $$aPsychotropic drugs$$zUnited States.
000246855 650_0 $$aBehavior disorders in children$$xTreatment$$zUnited States.
000246855 650_0 $$aAttention-deficit hyperactivity disorder$$xTreatment$$zUnited States.
000246855 650_0 $$aHyperactive children$$xBehavior modification$$zUnited States.
000246855 650_0 $$aMedication abuse$$zUnited States.
000246855 650_0 $$aStudents$$xMental health$$zUnited States.
000246855 85230 $$bdfich$$hY 4.ED 8/1:$$i106-130
000246855 909CO $$ooai:library.usi.edu:246855$$pGLOBAL_SET
000246855 980__ $$aBIB
000246855 980__ $$aGOV RESOURCE
000246855 994__ $$aE0$$bISE